{
  "uuid" : "",
  "id" : "ovarian_adjuvant_chemotherapy_early_stage.v0.0.1",
  "gdl_version" : "2.1",
  "concept" : "gt0001",
  "language" : {
    "original_language" : "ISO_639-1::en"
  },
  "description" : {
    "original_author" : {
      "name" : "Katja Mariko Wilde",
      "email" : "katja-wilde@t-online.de",
      "organisation" : "Cambio CDS",
      "date" : "2026-01-28"
    },
    "lifecycle_state" : "DRAFTED",
    "details" : {
      "en" : {
        "id" : "en",
        "purpose" : "To recommend an appropriate primary adjuvant chemotherapy regimen for patients with FIGO stage I ovarian, fallopian tube, or primary peritoneal carcinoma based on histology, tumour differentiation grade, stage subgroup, and lymph node dissection status.",
        "keywords" : [
          "ovarian",
          "fallopian tube",
          "primary peritoneal",
          "cancer",
          "adjuvant",
          "chemotherapy",
          "early stage",
          "figo",
          "histology",
          "treatment",
          "recommendation",
          "oncology"
        ],
        "use" : "Use to support decision-making for primary adjuvant chemotherapy in FIGO stage I ovarian, fallopian tube, and primary peritoneal carcinoma.\n\nThe guideline evaluates the following inputs:\n- Histology and differentiation grade (e.g. high-grade serous, endometrioid FIGO grade 1-3, clear cell, mucinous, low-grade serous, undifferentiated/carcinosarcoma)\n- FIGO stage subgroup (IA–B, IA–C, IC)\n- Lymph node dissection status (indicated, not performed, or not indicated)\n\nBased on these inputs, the guideline assigns one of the following outputs:\n- Carboplatin monotherapy (AUC 6), every 3 weeks for 6 cycles\n- Carboplatin (AUC 5) plus paclitaxel (175 mg/m²), every 3 weeks for 6 cycles\n- Carboplatin (AUC 5) plus paclitaxel (175 mg/m²), every 3 weeks for 4 cycles\n- No adjuvant chemotherapy recommended\n- Adjuvant chemotherapy cannot be determined based on available inputs\n\nThe recommendations reflect national clinical guidelines for adjuvant treatment in early-stage epithelial ovarian cancer.",
        "misuse" : "Not to be used for treatment planning in FIGO stage II-IV disease, for recurrent ovarian cancer, or for non-epithelial ovarian malignancies.",
        "copyright" : "© Cambio CDS"
      }
    },
    "other_details" : {
      "references" : "Regionala cancercentrum i samverkan. Nationellt vårdprogram Äggstockscancer med epitelial histologi: Kapitel 11 Primärbehandling. Kunskapsbanken, 2025. Available at: https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/",
      "en" : "A structured clinical guideline used to support recommendations for primary adjuvant chemotherapy in patients with FIGO stage I ovarian, fallopian tube, and primary peritoneal carcinoma."
    }
  },
  "definition" : {
    "data_bindings" : {
      "gt0002" : {
        "id" : "gt0002",
        "model_id" : "openEHR-EHR-OBSERVATION.ovarian_adjuvant_chemotherapy_early_stage.v0",
        "template_id" : "openEHR-EHR-OBSERVATION.ovarian_adjuvant_chemotherapy_early_stage.v0",
        "type" : "INPUT",
        "elements" : {
          "gt0003" : {
            "id" : "gt0003",
            "path" : "/data[at0001]/events[at0002]/data[at0003]/items[at0006]",
            "data_type" : "DV_CODED_TEXT",
            "allowed_values" : [
              "local::at0007",
              "local::at0008",
              "local::at0009",
              "local::at0010",
              "local::at0011",
              "local::at0012",
              "local::at0013",
              "local::at0014"
            ]
          },
          "gt0004" : {
            "id" : "gt0004",
            "path" : "/data[at0001]/events[at0002]/data[at0003]/items[at0015]",
            "data_type" : "DV_CODED_TEXT",
            "allowed_values" : [
              "local::at0016",
              "local::at0017",
              "local::at0018"
            ]
          },
          "gt0005" : {
            "id" : "gt0005",
            "path" : "/data[at0001]/events[at0002]/data[at0003]/items[at0019]",
            "data_type" : "DV_CODED_TEXT",
            "allowed_values" : [
              "local::at0020",
              "local::at0021",
              "local::at0022"
            ]
          }
        }
      },
      "gt0006" : {
        "id" : "gt0006",
        "model_id" : "openEHR-EHR-OBSERVATION.ovarian_adjuvant_chemotherapy_early_stage.v0",
        "template_id" : "openEHR-EHR-OBSERVATION.ovarian_adjuvant_chemotherapy_early_stage.v0",
        "type" : "OUTPUT",
        "elements" : {
          "gt0007" : {
            "id" : "gt0007",
            "path" : "/data[at0001]/events[at0002]/data[at0003]/items[at0023]",
            "data_type" : "DV_CODED_TEXT"
          }
        }
      }
    }
  },
  "ontology" : {
    "term_definitions" : {
      "en" : {
        "id" : "en",
        "terms" : {
          "gt0001" : {
            "id" : "gt0001",
            "text" : "Primary adjuvant chemotherapy for early-stage ovarian cancer",
            "description" : "A structured clinical guideline used to support recommendations for primary adjuvant chemotherapy in patients with FIGO stage I ovarian, fallopian tube, and primary peritoneal carcinoma."
          },
          "gt0002" : {
            "id" : "gt0002",
            "text" : "openEHR-EHR-OBSERVATION.ovarian_adjuvant_chemotherapy_early_stage.v0"
          },
          "gt0003" : {
            "id" : "gt0003",
            "text" : "Histology / differentiation grade"
          },
          "gt0004" : {
            "id" : "gt0004",
            "text" : "FIGO stage"
          },
          "gt0005" : {
            "id" : "gt0005",
            "text" : "Lymph node dissection status"
          },
          "gt0006" : {
            "id" : "gt0006",
            "text" : "openEHR-EHR-OBSERVATION.ovarian_adjuvant_chemotherapy_early_stage.v0"
          },
          "gt0007" : {
            "id" : "gt0007",
            "text" : "Primary adjuvant treatment"
          }
        }
      }
    }
  }
}